Synexa Joins CEPI in advancing global epidemic preparedness and response
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
With over 150 leading companies, 300+ topline brands and knowledge-led conference sessions, the event is set to make a grand return to the South
The company reported lifetime high EBIDTA of Rs. 250 crores
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
5C Network’s groundbreaking platform aims to bring together diagnostic facilities and healthcare aggregators on a single platform to deliver an unparalleled patient experience
Subscribe To Our Newsletter & Stay Updated